Contribution: Industrial Research Assistance Program – Contributions to Firms
WEX Pharmaceuticals Inc.
$328,984.00
Proof of concept study for combinations of tetrodotoxin (TTX) and current analgesics in chemotherapy pain management and the development of new formulations of TTX
FY 2016-17 · 2016-08-01
Summary
This project will attempt to demonstrate the synergistic effects of tetrodotoxin (TTX) and current analgesics for the treatment of chemotherapy induced peripheral neuropathy. A new TTX formulation will be developed that can be combined with currently available analgesics for a synergistic analgesic effect at a subsequent stage.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Vancouver|Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
104030796
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 5 | 2016-08-01 | 2016-17 | $19,000.00 |
| 6 | 2016-08-01 | 2016-17 | $328,984.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 181 days. The total amended value is 91,160 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 181 jours. La valeur totale des modifications est de 91 160 dollars.
Agreement End Date
2019-07-31
Agreement Number
870447
Agreement Start Date
2016-08-01
Agreement Title
Proof of concept study for combinations of tetrodotoxin (TTX) and current analgesics in chemotherapy pain management and the development of new formulations of TTX
Agreement Title (French)
Démonstration de faisabilité pour les combinaisons de la tétrodotoxine (TTX) et des analgésiques courants pour la gestion de douleur de chimiothérapie et le développement de nouvelles formulations de TTX
Agreement Type
Contribution
Agreement Value
$328,984.00
Amendment Date
2019-01-11
Amendment Number
6
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project will attempt to demonstrate the synergistic effects of tetrodotoxin (TTX) and current analgesics for the treatment of chemotherapy induced peripheral neuropathy. A new TTX formulation will be developed that can be combined with currently available analgesics for a synergistic analgesic effect at a subsequent stage.
Description (French)
Ce projet tentera de démontrer les effets synergiques de la tétrodotoxine (TTX) et des analgésiques courants pour le traitement de chimiothérapie induite par une neuropathie périphérique. Une nouvelle formulation de TTX sera développée, qui peut être combinée avec des analgésiques présentement disponibles pour un effet analgésique synergique à un stade subséquent.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Vancouver Centre
Federal Riding (French)
Vancouver-Centre
Federal Riding Number
59034
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
104030796
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
WEX Pharmaceuticals Inc.
Recipient Postal Code
V6E 4A6
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2018-2019-Q1-870447
